<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895722</url>
  </required_header>
  <id_info>
    <org_study_id>1308A-008</org_study_id>
    <secondary_id>2020-005114-18</secondary_id>
    <secondary_id>MK-1308A-008</secondary_id>
    <nct_id>NCT04895722</nct_id>
  </id_info>
  <brief_title>Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)</brief_title>
  <official_title>A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of pembrolizumab or&#xD;
      co-formulated pembrolizumab/quavonlimab in participants with MSI-H or dMMR Metastatic Stage&#xD;
      IV Colorectal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">September 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 19, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 39 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by BICR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1 as assessed by BICR</measure>
    <time_frame>Up to approximately 39 months</time_frame>
    <description>DOR is defined as the time from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) per RECIST 1.1 as assessed by BICR</measure>
    <time_frame>Up to approximately 39 months</time_frame>
    <description>PFS is defined as the time from randomization (or first dose) to the first documented PD per RECIST 1.1 assessed by BICR or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 39 months</time_frame>
    <description>OS is defined as the time from randomization (or first dose) to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experienced an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 27 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study intervention. The number of participants with an AE will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants discontinuing study treatment due to an AE</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study intervention. The number of participants that discontinue study treatment due to an AE will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive pembrolizumab 400 mg intravenously (IV) every 6 weeks (Q6W) for up to approximately 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab/Quavonlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) Q6W for up to approximately 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>400 mg pembrolizumab administered via IV infusion.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KeytrudaÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab/Quavonlimab</intervention_name>
    <description>Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.</description>
    <arm_group_label>Pembrolizumab/Quavonlimab</arm_group_label>
    <other_name>MK-1308A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a histologically confirmed diagnosis of Stage IV CRC adenocarcinoma (as defined by&#xD;
             American Joint Committee on Cancer [AJCC] version 8)&#xD;
&#xD;
          -  Has locally confirmed dMMR/MSI-H&#xD;
&#xD;
          -  Has a life expectancy of at least 3 months&#xD;
&#xD;
          -  Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 at&#xD;
             screening and within 3 days before Cycle 1 Day 1&#xD;
&#xD;
          -  Female participants are eligible to participate if not pregnant or breastfeeding, and&#xD;
             not a woman of childbearing potential (WOCBP), or if a WOCBP then is using a&#xD;
             contraceptive method that is highly effective or is abstinent on a long-term and&#xD;
             persistent basis, during the intervention period and for at least 120 days after the&#xD;
             last dose of study intervention&#xD;
&#xD;
          -  Has measurable disease per RECIST 1.1 as assessed by BICR&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Cohort A:&#xD;
&#xD;
          -  Has been previously treated for their disease and radiographically progressed per&#xD;
             RECIST 1.1 on or after or could not tolerate standard treatment, which must include&#xD;
             all of the following agents if approved and locally available in the country where the&#xD;
             participant is randomized:&#xD;
&#xD;
               -  Fluoropyrimidine, irinotecan and oxaliplatin (capecitabine is acceptable as&#xD;
                  equivalent to fluorouracil in prior therapy)&#xD;
&#xD;
               -  With or without an anti-vascular endothelial growth factor (VEGF) monoclonal&#xD;
                  antibody (e.g., bevacizumab)&#xD;
&#xD;
               -  At least one of the anti-epidermal growth factor receptor (EGFR) monoclonal&#xD;
                  antibodies (cetuximab or panitumumab) for rat sarcoma viral oncogene homolog&#xD;
                  (RAS) wild-type participants with left-sided tumors&#xD;
&#xD;
          -  Must not have had prior exposure to PD-1 or PD-L1 therapies as treatment for this&#xD;
             disease&#xD;
&#xD;
        Cohort B:&#xD;
&#xD;
        - Has untreated Stage IV dMMR/MSI-H CRC with no prior chemotherapy or immunotherapy for&#xD;
        this disease&#xD;
&#xD;
        Cohort C:&#xD;
&#xD;
          -  Has radiographically progressed on-treatment with an anti-PD-1 monoclonal antibody&#xD;
             (mAb) administered either as monotherapy or in combination with other therapies&#xD;
&#xD;
          -  Has had 0 to 1 prior systemic fluoropyrimidine based chemotherapy regimens&#xD;
&#xD;
          -  Must not have been treated in Cohort A&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received prior therapy with an agent directed to another stimulatory or&#xD;
             coinhibitory T-cell receptor&#xD;
&#xD;
          -  Has received prior systemic anticancer therapy including investigational agents within&#xD;
             4 weeks before the first dose of study intervention&#xD;
&#xD;
          -  Has not recovered adequately from a surgery procedure, and/or has any complications&#xD;
             from a prior surgery before starting study intervention&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study intervention&#xD;
&#xD;
          -  Has received a live or live-attenuated vaccine within 30 days before the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks before the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study medication&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 2 years&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis&#xD;
&#xD;
          -  Has severe hypersensitivity (â¥Grade 3) to pembrolizumab, quavonlimab and/or any of&#xD;
             their excipients&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs)&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy (e.g., tuberculosis, known viral or&#xD;
             bacterial infections, etc.)&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Has known active Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] positive&#xD;
             and/or detectable Hepatitis B Virus [HBV] deoxyribonucleic acid [DNA]) or active&#xD;
             Hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected or&#xD;
             anti-HCV antibodypositive) infection&#xD;
&#xD;
          -  Is pregnant, or breastfeeding, or expecting to conceive children within the projected&#xD;
             duration of the study, starting with the Screening Visit through 120 days after the&#xD;
             last dose of study intervention&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mid Florida Cancer Center ( Site 1519)</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-353-1915</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC ( Site 1521)</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-353-5006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC ( Site 1546)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>253-428-8700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0102)</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3281423857</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital-Oncology ( Site 0307)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>506-857-5669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers ( Site 0511)</name>
      <address>
        <city>Poitiers</city>
        <state>Ain</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33 5 49 44 44 44</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique HÃ´pitaux de Marseille - HÃ´pital de la Ti-Service d'Hepato-Gastro-Enterologie et</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491388472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil-Digestive oncology department ( Site 0502)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33561322142</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez - CHU de Lille ( Site 0510)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320445461</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint Antoine-Oncologie mÃ©dicale ( Site 0508)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33149282954</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 0601)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49 351 458 7683</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CharitÃ© Universitaetsmedizin Berlin - Campus Mitte ( Site 0604)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4930450613132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0802)</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223903835</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale-Department of Abdominal Oncology ( Site 0803)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3407844709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital-Hematology/oncology ( Site 1103)</name>
      <address>
        <city>Daegu</city>
        <state>Taegu-Kwangyokshi</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>053-200-3017</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 1107)</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8229206090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital-Internal Medicine ( Site 1101)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220720795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1104)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82 (2) 331 2471</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center-Department of Oncology ( Site 1105)</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82 (2) 331 2471</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center-Division of Hematology/Oncology ( Site 1102)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02-2148-7394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea Seoul St. Mary's Hospital-Medical Oncology ( Site 1106)</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82 (2) 331 2471</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Powiatowe Centrum Zdrowia ( Site 0911)</name>
      <address>
        <city>Brzeziny</city>
        <state>Lodzkie</state>
        <zip>95-060</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48426895477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luxmed Onkologia sp. z o. o. ( Site 0915)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48691666578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Onkologii i Radioterapii ( Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>225709223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mrukmed-Mrukmed ( Site 0901)</name>
      <address>
        <city>Rzeszow</city>
        <state>Podkarpackie</state>
        <zip>35-021</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48178502470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital WojewÃ³dzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0903)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>943488930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 1001)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast</state>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79111019156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology-Clinical Pharmacology and Chemotherapy</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79057043318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University I.M. Sechenov-Interhospital Institution Health Management Cl</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79199923977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rostov Cancer Research Institute ( Site 1014)</name>
      <address>
        <city>Rostov on Don</city>
        <state>Rostovskaya Oblast</state>
        <zip>344037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78632955374</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>GBUZ SPb CRPCstmc(o) ( Site 1005)</name>
      <address>
        <city>Sankt- Peterburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79112740104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary-Chemotherapy #3 ( Site 1006)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79172662851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias-Medical Oncology ( Site 1203)</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34985106100Ext36281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario MarquÃ©s de Valdecilla ( Site 1202)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34942202525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron ( Site 1201)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÃON ( Site 1206)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos-Oncology Department ( Site 1204)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913303000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi-oncology hospital ( Site 1301)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903123051080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1305)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+90216 606 52 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

